Longeveron Inc Dossier - Source-backed chat

Longeveron Inc

LGVNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.59Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $8.3M

Enterprise Value $3.6M

Shares Outstanding 3M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Longeveron Inc. is undergoing a strategic repositioning toward a capital-efficient, asset-light operating model focused on securing strategic licensing partnerships for its lead cellular therapeutic candidate, laromestrocel (Lomecel-B). The company is approaching a series of potentially transformative clinical milestones, most notably the top-line Phase 2b ELPIS II trial results in Hypoplastic Left Heart Syndrome (HLHS) expected in August 2026. With a strengthened balance sheet following a $30 million private placement and a disciplined cost structure, Longeveron represents a high-upside clinical-stage biotechnology opportunity with multiple FDA expedited designations.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$7.15

High · most bullish analyst$10.45

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

The ELPIS II trial results in HLHS are ambiguous or fail to meet statistical significance, delaying or halting the BLA pathway. The company is unable to secure strategic licensing partners or non-dilutive funding for its Alzheimer's program, forcing highly dilutive equity raises to fund operations beyond late 2026. The stock faces downward pressure, trading down toward the lower-end analyst target of $3.00.

Base CaseCentral scenario

$5.5050%

The ELPIS II trial meets its primary endpoints, confirming laromestrocel as a viable adjunct treatment for HLHS. Longeveron leverages these results to advance regulatory discussions with the FDA and progress toward a BLA. The company successfully extends its cash runway through disciplined spending and initial regional licensing partnerships, while continuing to generate steady clinical trial revenue from its Bahamas Registry Trial. The stock moves toward the consensus analyst target of $5.50.

Bull CaseUpside scenario

$8.0030%

The Phase 2b ELPIS II trial in HLHS yields highly positive top-line results in August 2026, validating laromestrocel's efficacy and paving the way for a BLA submission in 2027. This success triggers the remaining $15 million milestone-driven funding from the private placement and attracts lucrative global licensing partnerships. Concurrently, the company secures non-dilutive funding to initiate the pivotal Phase 2/3 trial in Alzheimer's disease in late 2026, driving substantial valuation expansion toward the high-end analyst target of $8.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transformative near-term catalyst with Phase 2b ELPIS II HLHS top-line data expected in August 2026.
Strategic pivot to a capital-efficient, asset-light operating model focused on high-value licensing partnerships.
Robust pipeline with laromestrocel addressing multiple high-value indications including HLHS, Alzheimer's disease, and Aging-related Frailty.
Strong regulatory backing with five distinct FDA designations, including RMAT and Fast Track for Alzheimer's disease.
Improved financial position with $15.8 million in cash as of Q1 2026 and up to $30 million in total private placement capacity.

Key Investment Risks

High binary clinical development risk associated with the upcoming ELPIS II trial results.
Limited cash runway extending only into the fourth quarter of 2026, necessitating additional capital or partnerships.
Dependence on securing non-dilutive funding or strategic partners to initiate the pivotal Alzheimer's trial.
Potential for future equity dilution if milestone-driven funding or partnerships do not materialize.

Thesis Invalidation Triggers

Failure of the Phase 2b ELPIS II trial to meet its primary efficacy or safety endpoints.
Inability to secure strategic licensing partnerships or non-dilutive funding by late 2026.
Regulatory delays or negative feedback from the FDA regarding the BLA pathway for HLHS or the Phase 2/3 design for Alzheimer's.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.